Mirvie Inc

9 articles about Mirvie Inc

• Mirvie Announces Completion of Enrollment of 10,000 Person Landmark Research Study for Pregnancy Health

  11/14/2023

  Study with leading physician-scientists will provide unprecedented insights into the underlying biology of pregnancy to identify those most at risk for adverse pregnancy complications that affect 1 in 5 pregnancies

• Mirvie Becomes First RNA-Based Pregnancy Health-Focused Company to Receive Clinical Laboratory Improvement Amendments (CLIA) Certification

  9/26/2023

  Mirvie has been certified by the Centers for Medicare and Medicaid Services (CMS) under the Clinical Laboratory Improvement Amendments (CLIA) to perform high-complexity clinical testing.

• Mirvie Receives $4.6 Million Grant to Study Objective Prediction of Preeclampsia in Sub-Saharan Africa

  8/2/2023

  Mirvie announced a $4.6 million grant from the Bill & Melinda Gates Foundation to support the company’s efforts to predict unexpected pregnancy complications before they happen by revealing the underlying biology of each pregnancy for women on a global scale.

• First Comprehensive Care Plan to Prevent Preeclampsia Published in the American Journal of Obstetrics and Gynecology

  4/28/2023

  A new special report published in the American Journal of Obstetrics and Gynecology provides a groundbreaking approach to preeclampsia, one of the most pressing issues in maternal health and will translate the prediction of risk into prevention of disease.

• Mirvie Expands Leadership Team with Appointment of Alison Cowan, M.D. as Head of Medical Affairs

  8/30/2022

  Mirvie, a pioneer in predicting unexpected pregnancy complications, announced the appointment of Alison Cowan, M.D., M.S.C.R. as Head of Medical Affairs.

• 

  Money on the Move: SwanBio, Remix, Locus, Mirvie and More

  5/18/2022

  Recent funding saw support for a platform that selectively degrades DNA, software to help read mammograms and a company using corn genetics to develop cancer-targeting viruses.

• Mirvie Raises $60 Million Funding Round to Shape the Future of Pregnancy Health

  5/17/2022

  Mirvie, a pioneer in predicting unexpected pregnancy complications, announced it has raised a total of $90 million to date following the close of its Series B funding.

• Late-breaking Data Presented at SMFM 2022 Annual Meeting Shows The Mirvie RNA Platform is First to Reveal The Underlying Biology of Preterm Birth

  2/4/2022

  Mirvie, a pioneer in predicting unexpected pregnancy complications, announced data presented at the Society for Maternal-Fetal Medicine 42nd Annual Pregnancy Meeting demonstrates the Mirvie RNA platform is first to predict preterm birth by revealing the underlying biology of each pregnancy.

• Study Published in Nature Shows Mirvie Can Predict Pregnancy Complications Months Before They Happen Using New, Proprietary RNA Platform

  1/5/2022

  Mirvie, a pioneer in predicting unexpected pregnancy complications, today announced the publication of a study in Nature proving the proprietary Mirvie RNA platform is first to predict unexpected complications by revealing the underlying biology of each pregnancy.